RGC

Regencell Bioscience Holdings Ltd Health Care Medicinal Chemicals & Botanical Products Russell 3000

$6.71Close $3.3BMarket cap $4.78 – $52.8852-week range

Highlights

Strengths

Accumulation up-day volume 2.0× down-day volume over 50 sessions

Cautions

Not in an uptrend 1 of 8 trend conditions
Lagging the market RS 5 · weaker than 95% of stocks over 12 months
Far from its high 87% below its 52-week high

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Jun 30, 2025 · filed Oct 31, 2025

Off 12-month high 87%

1wk 12.5% price change

1mo 7.9% price change

12-month return 59% market up 11% · its own down 70%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 682.7× price / book

Earnings yield 0.1% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 55% return on equity

Free cash margin — -$3.3M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 15.2% $1.02 a day · 2×ATR $4.67

RS 5 / 99 vs the universe

Trend 1 / 8 trend template

Relative volume 0.6× vs 50-day average

Up/down volume 1.99 50 sessions

Implied move — no scheduled report

Trend template · 1 of 8

At least 30% above the 52-week low: passes

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last shock Oct 23, 2026-22% in one session1.9× volumeno filing matched-13% since

Financials

6 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$3.6M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$3.3M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 494.49m +4844.9% since FY2020

	FY2020Jun 30, 2020	FY2021Jun 30, 2021	FY2022Jun 30, 2022	FY2023Jun 30, 2023	FY2024Jun 30, 2024	FY2025Jun 30, 2025
Operating income	-$812,371	-$1.4M	-$7.6M	-$6.3M	-$4.7M	-$3.8M
Net income	-$812,371	-$1.3M	-$7.4M	-$5.9M	-$4.3M	-$3.6M
Earnings per share	-$0.08	-$0.13	-$0.58	-$0.01	-$0.01	-$0.01
Free cash flow	-$844,410	-$767,311	-$6.0M	-$5.0M	-$4.0M	-$3.3M
Cash	$386,979	$59,413	$6.4M	$1.6M	$3.0M	$2.4M
Shareholders' equity	-$2.7M	-$4.0M	$17.1M	$12.0M	$8.2M	$4.9M
Shares outstanding	10m	10m	13.01m	13.01m	494.49m	494.49m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Oct 31, 2025	Annual ↗	Jun 30, 2025	123d
Oct 25, 2024	Annual ↗	Jun 30, 2024	117d
Oct 27, 2023	Annual ↗	Jun 30, 2023	119d
Oct 31, 2022	Annual ↗	Jun 30, 2022	123d
Oct 29, 2021	Annual ↗	Jun 30, 2021	121d

Current reports

Filed	Disclosed
May 22, 2026	Foreign issuer report ↗
May 19, 2026	Foreign issuer report ↗
May 19, 2026	Foreign issuer report ↗
May 8, 2026	Foreign issuer report ↗
Apr 17, 2026	Foreign issuer report ↗
Mar 30, 2026	Foreign issuer report ↗
Mar 30, 2026	Foreign issuer report ↗
Feb 13, 2026	Foreign issuer report ↗
Jun 30, 2025	Foreign issuer report ↗
Jun 30, 2025	Foreign issuer report ↗
Jun 17, 2025	Foreign issuer report ↗
Jun 2, 2025	Foreign issuer report ↗